[go: up one dir, main page]

PE20211780A1 - Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp) - Google Patents

Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp)

Info

Publication number
PE20211780A1
PE20211780A1 PE2021000596A PE2021000596A PE20211780A1 PE 20211780 A1 PE20211780 A1 PE 20211780A1 PE 2021000596 A PE2021000596 A PE 2021000596A PE 2021000596 A PE2021000596 A PE 2021000596A PE 20211780 A1 PE20211780 A1 PE 20211780A1
Authority
PE
Peru
Prior art keywords
pyrimidinodiona
tetrahydropyrane
thp
cyclic
compounds replaced
Prior art date
Application number
PE2021000596A
Other languages
English (en)
Inventor
Mark Grillo
Brian Kane
Johan Oslob
Min Zhong
Fabienne Thompson
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of PE20211780A1 publication Critical patent/PE20211780A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Un compuesto que tiene la formula (i) o una sal farmaceuticamente aceptable del mismo, en el que el subindice n es 1 o 2; cada R 1 es un miembro seleccionado del grupo que consiste en fluor, cloro, alquilo opcionalmente sustituido C1-C4, uno de R2a y R2b es fluor y el otro de R2a y R2b es H. Son utiles para el tratamiento de la cardiomiopatia hipertrofica (HCM) y las condiciones asociadas con la hipertrofia ventricular izquierda o la disfuncion diastolica, y/o los sintomas asociados a la misma.
PE2021000596A 2018-10-29 2019-10-28 Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp) PE20211780A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752278P 2018-10-29 2018-10-29
PCT/US2019/058297 WO2020092208A1 (en) 2018-10-29 2019-10-28 Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds

Publications (1)

Publication Number Publication Date
PE20211780A1 true PE20211780A1 (es) 2021-09-08

Family

ID=68841171

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000596A PE20211780A1 (es) 2018-10-29 2019-10-28 Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp)

Country Status (29)

Country Link
US (5) US11034693B2 (es)
EP (2) EP4464321B1 (es)
JP (3) JP7447110B2 (es)
KR (2) KR102797129B1 (es)
CN (3) CN119977963A (es)
AR (1) AR116880A1 (es)
AU (2) AU2019373206B2 (es)
BR (1) BR112021008077A2 (es)
CA (1) CA3118293A1 (es)
CL (1) CL2021001083A1 (es)
CO (1) CO2021005540A2 (es)
DK (1) DK3873904T3 (es)
EA (1) EA202191152A1 (es)
ES (1) ES2986923T3 (es)
FI (1) FI3873904T3 (es)
HR (1) HRP20241065T1 (es)
HU (1) HUE068265T2 (es)
IL (2) IL282740B1 (es)
LT (1) LT3873904T (es)
MX (2) MX2021004955A (es)
PE (1) PE20211780A1 (es)
PL (1) PL3873904T3 (es)
PT (1) PT3873904T (es)
RS (1) RS65963B1 (es)
SG (1) SG11202104218SA (es)
SI (1) SI3873904T1 (es)
SM (1) SMT202400358T1 (es)
TW (3) TWI876902B (es)
WO (1) WO2020092208A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111868063B (zh) 2018-01-17 2023-08-01 葛兰素史克知识产权开发有限公司 PI4KIIIβ抑制剂
JP7447110B2 (ja) * 2018-10-29 2024-03-11 マイオカーディア,インク テトラヒドロピラン(thp)-置換二環式-ピリミジンジオン化合物
JP2023540485A (ja) * 2020-08-28 2023-09-25 マイオカーディア,インク ミオシンモジュレーターによる治療方法
CN114149423B (zh) * 2020-09-08 2023-12-12 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114456163B (zh) * 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
AU2021381664A1 (en) 2020-11-20 2023-06-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
AU2022229390A1 (en) 2021-03-04 2023-09-21 Cytokinetics, Inc. Cardiac sarcomere inhibitors
CN119053591A (zh) 2022-05-20 2024-11-29 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的晶型及制备方法
JP2025525093A (ja) 2022-07-29 2025-08-01 マイオカーディア,インク (6S,7S)-6-フルオロ-7-(2-フルオロ-5-メチルフェニル)-3-(テトラヒドロ-2H-ピラン-4-イル)-5,6,7,8-テトラヒドロピリド[2,3-d]ピリミジン-2,4(1H,3H)-ジオン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69617235T2 (de) 1995-06-07 2002-07-25 G.D. Searle & Co., Chicago Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9663516B2 (en) * 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
JP7447110B2 (ja) 2018-10-29 2024-03-11 マイオカーディア,インク テトラヒドロピラン(thp)-置換二環式-ピリミジンジオン化合物

Also Published As

Publication number Publication date
US20250282779A1 (en) 2025-09-11
ES2986923T3 (es) 2024-11-13
TWI876902B (zh) 2025-03-11
BR112021008077A2 (pt) 2021-08-03
JP2025138748A (ja) 2025-09-25
AU2025200975A1 (en) 2025-03-06
HUE068265T2 (hu) 2024-12-28
CO2021005540A2 (es) 2021-07-30
EP4464321A3 (en) 2025-01-01
CN113056465A (zh) 2021-06-29
US20200165247A1 (en) 2020-05-28
TW202030189A (zh) 2020-08-16
JP2024063091A (ja) 2024-05-10
WO2020092208A1 (en) 2020-05-07
SI3873904T1 (sl) 2024-10-30
FI3873904T3 (fi) 2024-08-09
LT3873904T (lt) 2024-11-11
AU2019373206B2 (en) 2024-11-14
AR116880A1 (es) 2021-06-23
KR102797129B1 (ko) 2025-04-18
US20220106314A1 (en) 2022-04-07
MX2024004892A (es) 2024-05-07
SG11202104218SA (en) 2021-05-28
JP7447110B2 (ja) 2024-03-11
US11034693B2 (en) 2021-06-15
MX2021004955A (es) 2021-07-21
HRP20241065T1 (hr) 2024-11-08
IL282740B1 (en) 2026-01-01
EP4464321A2 (en) 2024-11-20
JP7703716B2 (ja) 2025-07-15
CL2021001083A1 (es) 2021-09-24
AU2019373206A1 (en) 2021-06-17
KR20250053228A (ko) 2025-04-21
CN119977963A (zh) 2025-05-13
IL282740A (en) 2021-06-30
US20220340569A1 (en) 2022-10-27
RS65963B1 (sr) 2024-10-31
SMT202400358T1 (it) 2024-11-15
EP4464321B1 (en) 2026-01-21
EA202191152A1 (ru) 2022-01-19
TW202521537A (zh) 2025-06-01
EP3873904A1 (en) 2021-09-08
KR20210086673A (ko) 2021-07-08
JP2022506524A (ja) 2022-01-17
IL325304A (en) 2026-02-01
CA3118293A1 (en) 2020-05-07
CN113056465B (zh) 2025-01-28
US12344607B2 (en) 2025-07-01
TW202426449A (zh) 2024-07-01
CN119977962A (zh) 2025-05-13
US20240025894A1 (en) 2024-01-25
TWI837202B (zh) 2024-04-01
PL3873904T3 (pl) 2024-12-23
EP3873904B1 (en) 2024-07-10
DK3873904T3 (da) 2024-08-05
PT3873904T (pt) 2024-10-08

Similar Documents

Publication Publication Date Title
PE20211780A1 (es) Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp)
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
AR114803A1 (es) Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
CY1124737T1 (el) Ανταγωνιστες lpa
CO2021016504A2 (es) Inhibidores de cdk
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
SV2017005384A (es) Compuestos aminopirimidinilo
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
PE20171511A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
AR118555A1 (es) Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
DOP2022000066A (es) Moduladores de sting (estimulador de genes de interferón)
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
CU20210035A7 (es) Compuestos de azalactam como inhibidores de hpk 1
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
CL2021000196A1 (es) Método de tratamiento de la epilepsia
PE20212070A1 (es) Moduladores de trex1
PE20180687A1 (es) Reactivos quirales para la preparacion de oligomeros homogeneos
PE20251594A1 (es) Derivado policiclico de carbamoilpiridona
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
MX385276B (es) Tratamiento para la enfermedad de parkinson
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
AR118729A1 (es) Inhibidor selectivo de la jak1 quinasa
EA201791667A1 (ru) Соединения бензоксаборола и их применение